Breakthrough in understanding of the mechanisms of pancreatic cancer
This biomedical research conducted jointly by the groups of Dr. Frédérick Antoine Mallette (Université de Montréal / Centre de Recherche HMR) and Dr. Stéphane Richard (McGill University / Lady Davis Institute for Medical Research) has shown that pancreatic tumours often lose the ability to express a small ribonucleic acid molecule called miR-137. This molecule induces a defence mechanism called cellular senescence, which keeps cancer cells in check. The loss of miR-137 works in conjunction with various mutations frequently observed in pancreatic tumours to trigger uncontrolled cell growth and then cancer.
"It is essential that we better understand the mechanisms that lead to the loss of miR-137 expression. Once we do, we can create therapeutic strategies to treat and prevent pancreatic cancer," said Dr. Frédérick Antoine Mallette.
This joint research study by doctoral student Mathieu Neault has also demonstrated that restoring normal miR-137 levels in pancreatic cancer cells has a protective effect, as doing so induces senescence and stops the cells from spreading.
Original publication
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.